Novo Nordisk states that it spent decades conducting research and investing billions of dollars to develop semaglutide and bring its products to market through the Food and Drug Administrations approval process
For researchers who need pure GLP-1 agonism without confounding from GIP and glucagon pathways, semaglutide remains the better choice
This approach means taking your total weekly dose and breaking it into smaller, more frequent injections instead of one single shot
Consider consulting with both types of providers before making a decision
Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease Dementia: A randomized clinical trial
424 In AD, GLP-1(7-36) amide inhibits IL-1 transcription and prevents cognitive dysfunction, amyloid precursor protein synthesis, and cell death